[go: up one dir, main page]

CO2017012362A2 - Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso - Google Patents

Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso

Info

Publication number
CO2017012362A2
CO2017012362A2 CONC2017/0012362A CO2017012362A CO2017012362A2 CO 2017012362 A2 CO2017012362 A2 CO 2017012362A2 CO 2017012362 A CO2017012362 A CO 2017012362A CO 2017012362 A2 CO2017012362 A2 CO 2017012362A2
Authority
CO
Colombia
Prior art keywords
dosage forms
palbociclib
solid dosage
production
methods
Prior art date
Application number
CONC2017/0012362A
Other languages
English (en)
Inventor
Fady Makram Louiz Ibrahim
Matthew Patrick Mullarney
Ravi Mysore Shanker
Barbara Rodriguez Spong
Jian Wang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56092955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017012362(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CO2017012362A2 publication Critical patent/CO2017012362A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a formas de dosificación sólidas tales como un comprimido, incluyendo comprimidos monocapa o bicapa de palbociclib que comprenden un ácido soluble en agua. Las formas de dosificación descritas en este documento tienen características farmacocinéticas deseables.
CONC2017/0012362A 2015-06-04 2017-11-30 Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso CO2017012362A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562171177P 2015-06-04 2015-06-04
US201662332973P 2016-05-06 2016-05-06
PCT/IB2016/053040 WO2016193860A1 (en) 2015-06-04 2016-05-24 Solid dosage forms of palbociclib

Publications (1)

Publication Number Publication Date
CO2017012362A2 true CO2017012362A2 (es) 2018-03-28

Family

ID=56092955

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0012362A CO2017012362A2 (es) 2015-06-04 2017-11-30 Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso

Country Status (31)

Country Link
US (2) US11065250B2 (es)
EP (2) EP3302565B1 (es)
JP (3) JP2017002034A (es)
KR (2) KR102369405B1 (es)
CN (2) CN113616606A (es)
AU (2) AU2016272881C1 (es)
BR (1) BR112017025398A2 (es)
CA (1) CA2931892A1 (es)
CL (1) CL2017003089A1 (es)
CO (1) CO2017012362A2 (es)
CR (1) CR20170540A (es)
CY (1) CY1122454T1 (es)
DK (1) DK3302565T3 (es)
DO (1) DOP2017000280A (es)
ES (1) ES2764459T3 (es)
HK (1) HK1250570A1 (es)
HR (1) HRP20192065T1 (es)
HU (1) HUE047477T2 (es)
IL (2) IL255632A (es)
LT (1) LT3302565T (es)
MX (2) MX376083B (es)
PE (1) PE20180395A1 (es)
PL (1) PL3302565T3 (es)
PT (1) PT3302565T (es)
RS (1) RS59672B1 (es)
RU (1) RU2686840C1 (es)
SA (1) SA517390473B1 (es)
SI (1) SI3302565T1 (es)
TW (2) TWI763881B (es)
WO (1) WO2016193860A1 (es)
ZA (1) ZA201707780B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628319B1 (en) 2008-10-02 2024-02-14 Salix Pharmaceuticals, Ltd. Treatment of hepatic encephalopathy using rifaximin
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
CN105816437B (zh) * 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US10449195B2 (en) * 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN108210454A (zh) * 2016-12-14 2018-06-29 深圳市华力康生物医药有限公司 一种帕布昔利布的口服乳剂及其制备方法
CA3050696A1 (en) * 2017-01-20 2018-07-26 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
ES2958616T3 (es) * 2017-03-08 2024-02-12 Cinrx Pharma Llc Formulaciones farmacéuticas de floroglucinol y trimetilfloroglucinol
US20200054560A1 (en) * 2017-04-21 2020-02-20 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
JP2020521795A (ja) * 2017-05-31 2020-07-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング （Ｅ）−４−（２−（アミノメチル）−３−フルオロアリルオキシ）−Ｎ−ｔｅｒｔ−ブチルベンズアミドを含む医薬組成物および医薬剤形、それらの調製方法、治療方法およびそれらの使用
CN106970177B (zh) * 2017-06-06 2018-05-15 北京元延医药科技股份有限公司 帕博西尼中间体及其杂质的分析检测方法
BR112020000318A2 (pt) 2017-07-10 2020-07-14 Takeda Pharmaceutical Company Limited preparação
WO2019020715A1 (en) * 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB
CN110997666A (zh) * 2017-09-19 2020-04-10 浙江华海药业股份有限公司 N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法
TWI803530B (zh) * 2017-10-27 2023-06-01 美商普雷辛肯公司 調節激酶之化合物之調配物
CN108014343A (zh) * 2017-12-21 2018-05-11 孟斯琴 一种治疗乳腺癌的药物组合物及其制备方法
CN108066303A (zh) * 2017-12-31 2018-05-25 湖南博隽生物医药有限公司 一种抗癌药物组合物及其制备方法
EP3758753A1 (en) 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
CA3100144C (en) 2018-05-14 2023-10-03 Pfizer Inc. Oral solution formulation of palbociclib in malic or lactic acid buffer
CN110719782B (zh) * 2018-05-15 2023-02-07 江苏豪森药业集团有限公司 包含第三代小分子egfr抑制剂的药物组合物及其制备方法
CN108653222A (zh) * 2018-07-03 2018-10-16 威海贯标信息科技有限公司 一种帕博西尼片剂组合物
CN109575021B (zh) * 2019-01-22 2020-09-18 北京海美桐医药科技有限公司 一种哌柏西利的制备方法
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
MX2021012310A (es) * 2019-04-11 2021-11-12 Goldfinch Bio Inc Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona.
CA3164619A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
IL293940A (en) 2019-12-16 2022-08-01 Lunella Biotech Inc Selective cancer drugs cdk4/6 inhibitors
PE20230992A1 (es) * 2020-06-19 2023-06-23 Acerta Pharma Bv Formas farmaceuticas de maleato de acalabrutinib
US20230364063A1 (en) * 2020-07-02 2023-11-16 Artham Therapeutics Inc. Oral pharmaceutical composition and method for producing same
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
CN114246872B (zh) * 2020-09-24 2024-02-06 南京济群医药科技股份有限公司 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
TW202500155A (zh) * 2023-06-12 2025-01-01 美商亞文納營運公司 雌激素受體降解劑之固體口服劑型
KR20250048897A (ko) 2023-10-04 2025-04-11 삼진제약주식회사 용해도 및 안정성이 개선된 팔보시클립을 포함하는 약학 조성물
KR20250062261A (ko) 2023-10-30 2025-05-08 신풍제약주식회사 향상된 용해도 및 안정성을 가지는 팔보시클립의 제약학적 조성물 및 이의 제조방법
WO2025156193A1 (en) * 2024-01-25 2025-07-31 Zhejiang Qizheng Pharmaceutical Co., Ltd. Palbociclib dosage form

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
BR9713552A (pt) 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
JP4291696B2 (ja) 2002-01-22 2009-07-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
JP4053073B2 (ja) * 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
CA2619035A1 (en) * 2005-08-22 2007-03-01 Novartis Ag Pharmaceutical compositions
KR20140088230A (ko) 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
AU2007297286A1 (en) 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
HRP20110621T2 (hr) 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
EP2482803B1 (en) * 2009-09-30 2021-12-22 Merck Sharp & Dohme (UK) Limited Formulations for c-met kinase inhibitors
AU2011264993B2 (en) * 2010-06-09 2014-02-06 Abbvie Bahamas Ltd. Solid dispersions containing kinase inhibitors
EP2782557B1 (en) 2011-11-23 2018-09-12 Array Biopharma, Inc. Pharmaceutical formulations
EP2793864A1 (en) 2011-12-22 2014-10-29 Boehringer Ingelheim International GmbH Immediate release multi unit pellet system
CA2900322C (en) 2013-02-21 2019-03-26 Pfizer Inc. Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
MX378263B (es) * 2013-08-14 2025-03-10 Novartis Ag Terapia de combinación para el tratamiento del cáncer.
JP2016537345A (ja) * 2013-11-13 2016-12-01 ノバルティス アーゲー 免疫応答を増強するためのｍＴＯＲ阻害剤
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof

Also Published As

Publication number Publication date
DOP2017000280A (es) 2018-01-15
EP3302565B1 (en) 2019-11-06
CA2931892A1 (en) 2016-12-04
KR20180015232A (ko) 2018-02-12
HK1250570A1 (zh) 2018-12-28
MX376083B (es) 2025-03-07
DK3302565T3 (da) 2020-01-02
RS59672B1 (sr) 2020-01-31
MX2017015579A (es) 2018-03-27
AU2019204689B2 (en) 2020-12-03
KR102068423B1 (ko) 2020-01-20
PL3302565T3 (pl) 2020-06-01
US20210315900A1 (en) 2021-10-14
BR112017025398A2 (pt) 2018-08-07
TWI635863B (zh) 2018-09-21
TWI763881B (zh) 2022-05-11
US20180207100A1 (en) 2018-07-26
AU2019204689A1 (en) 2019-07-18
PT3302565T (pt) 2020-01-14
JP2023112149A (ja) 2023-08-10
HUE047477T2 (hu) 2020-04-28
US11065250B2 (en) 2021-07-20
CY1122454T1 (el) 2021-01-27
CR20170540A (es) 2018-02-02
JP2021167343A (ja) 2021-10-21
EP3302565A1 (en) 2018-04-11
ZA201707780B (en) 2020-05-27
TW201906611A (zh) 2019-02-16
HRP20192065T1 (hr) 2020-02-21
JP2017002034A (ja) 2017-01-05
AU2016272881A1 (en) 2017-12-07
EP3636283A1 (en) 2020-04-15
IL287437A (en) 2021-12-01
ES2764459T3 (es) 2020-06-03
LT3302565T (lt) 2019-12-27
MX2020003825A (es) 2020-08-06
SA517390473B1 (ar) 2022-12-11
AU2016272881B2 (en) 2019-04-11
NZ737391A (en) 2023-11-24
CN113616606A (zh) 2021-11-09
KR102369405B1 (ko) 2022-03-02
KR20200006633A (ko) 2020-01-20
PE20180395A1 (es) 2018-02-28
TW201711687A (zh) 2017-04-01
CN107666914A (zh) 2018-02-06
SI3302565T1 (sl) 2020-02-28
IL255632A (en) 2018-01-31
RU2686840C1 (ru) 2019-05-06
CL2017003089A1 (es) 2018-05-11
JP7627302B2 (ja) 2025-02-05
AU2016272881C1 (en) 2019-10-03
WO2016193860A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
CO2017012362A2 (es) Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso
IL269444B (en) New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs
UY34651A (es) ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?..
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
NI201500167A (es) Compuestos químicos
MX386584B (es) Composiciones de liberación retardada de linaclotida.
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
ECSP17011672A (es) Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
EP3661489A4 (en) COMPOSITION OF FLOTTABLE PHARMACEUTICAL MICROCAPSULE
BR112012028788A2 (pt) fabricação de grânulos sem ativos
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
UY37193A (es) Nuevos compuestos antivíricos
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CR20160133A (es) Derivados de fenilalanina sustituidos
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
NI201900023A (es) 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
DK3258920T3 (da) Fast farmaceutisk doseringsform, der er egnet til anvendelse som drikkevandsmedikament
WO2014155389A3 (en) Process for preparation of ticagrelor
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
MX381148B (es) Polipéptidos de acción prolongada y métodos para su producción y administración.
HK1245155A1 (zh) 制备去氧肾上腺素树脂酸盐颗粒的方法；去氧肾上腺素树脂酸盐颗粒；以及去氧肾上腺素树脂酸盐颗粒在药物制剂中的用途
HUE053816T2 (hu) Rivasztigmin tartalmú elnyújtott felszabadulású gyógyszerészeti készítmény